293 related articles for article (PubMed ID: 33090679)
1. Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
Bubu OM; Umasabor-Bubu OQ; Turner AD; Parekh A; Mullins AE; Kam K; Birckbichler MK; Mukhtar F; Mbah AK; Williams NJ; Rapoport DM; de Leon M; Jean-Louis G; Ayappa I; Varga AW; Osorio RS;
Alzheimers Dement; 2020 Oct; ():. PubMed ID: 33090679
[TBL] [Abstract][Full Text] [Related]
2. Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes.
Bubu OM; Pirraglia E; Andrade AG; Sharma RA; Gimenez-Badia S; Umasabor-Bubu OQ; Hogan MM; Shim AM; Mukhtar F; Sharma N; Mbah AK; Seixas AA; Kam K; Zizi F; Borenstein AR; Mortimer JA; Kip KE; Morgan D; Rosenzweig I; Ayappa I; Rapoport DM; Jean-Louis G; Varga AW; Osorio RS;
Sleep; 2019 Jun; 42(6):. PubMed ID: 30794315
[TBL] [Abstract][Full Text] [Related]
3. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
5. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia.
Shen XN; Li JQ; Wang HF; Li HQ; Huang YY; Yang YX; Tan L; Dong Q; Yu JT;
Alzheimers Dement (Amst); 2020; 12(1):e12104. PubMed ID: 33005724
[TBL] [Abstract][Full Text] [Related]
6. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
7. Disease trajectories in elders with suspected non-Alzheimer's pathophysiology and its comparison with Alzheimer's disease pathophysiology: a longitudinal study.
Li JQ; Song JH; Suckling J; Wang YJ; Zuo CT; Zhang C; Gao J; Song YQ; Xie AM; Tan L; Yu JT
Res Sq; 2023 Mar; ():. PubMed ID: 37034751
[TBL] [Abstract][Full Text] [Related]
8. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
10. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
[TBL] [Abstract][Full Text] [Related]
12. Obstructive sleep apnea and Alzheimer's disease-related cerebrospinal fluid biomarkers in mild cognitive impairment.
Díaz-Román M; Pulopulos MM; Baquero M; Salvador A; Cuevas A; Ferrer I; Ciopat O; Gómez E
Sleep; 2021 Jan; 44(1):. PubMed ID: 32728730
[TBL] [Abstract][Full Text] [Related]
13. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease.
Pfeil J; Hoenig MC; Doering E; van Eimeren T; Drzezga A; Bischof GN;
Neurobiol Aging; 2021 Oct; 106():119-129. PubMed ID: 34284259
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
15. P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders.
Ma LZ; Hu H; Wang ZT; Ou YN; Dong Q; Tan L; Yu JT
Alzheimers Res Ther; 2021 Dec; 13(1):200. PubMed ID: 34911582
[TBL] [Abstract][Full Text] [Related]
16. A Candidate Regulatory Variant at the
Tian ML; Ni XN; Li JQ; Tan CC; Cao XP; Tan L;
Front Neurosci; 2019; 13():742. PubMed ID: 31379492
[No Abstract] [Full Text] [Related]
17. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
18. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
[TBL] [Abstract][Full Text] [Related]
19. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
20. Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer's disease.
Xie L; Das SR; Wisse LEM; Ittyerah R; de Flores R; Shaw LM; Yushkevich PA; Wolk DA;
Alzheimers Res Ther; 2023 Apr; 15(1):79. PubMed ID: 37041649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
